The appointment signals a focus on regulatory preparedness for zorevunersen. Traders should monitor for upcoming Phase 3 data readouts and potential regulatory milestones, which this addition to the board may help facilitate.
Price Chart
Executive Summary
Stoke Therapeutics appointed Dr. Clare Kahn, a seasoned biotech executive with deep regulatory and drug development expertise, to its board of directors. The move strengthens governance ahead of key Phase 3 data readouts for its lead candidate, zorevunersen, in Dravet syndrome.
Key Facts
- Dr. G. Clare Kahn, Ph.D., was appointed to Stoke's Board of Directors effective April 3, 2026.
- Dr. Kahn brings over three decades of industry experience, including senior roles at Pfizer, GSK, and X-VAX Technology Inc., with expertise in rare disease drug development and regulatory strategy.
- She was also appointed chairperson of the Research and Development Committee and to the Nominating and Corporate Governance Committee.
- The board size was increased to ten directors to accommodate the appointment.
- Dr. Kahn received an initial stock option grant valued at approximately $724,000 and will receive an annual cash retainer of $45,000.
Financial Impact
Approximately $724,000 in initial stock option grant value and $45,000 annual cash retainer for Dr. Kahn's board service.
Risk Factors
- Biotech clinical-stage risk: The company's value is highly dependent on the success of zorevunersen, which is still in development.
- Dilution risk: The stock option grant, while standard for board appointments, represents a small degree of shareholder dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-145524 |
| Document: d63742dex991.htm | 0001193125-26-145524 |
| Document: 0001193125-26-145524-index-headers.html | 0001193125-26-145524 |
| Document: 0001193125-26-145524-index.html | 0001193125-26-145524 |
| Document: 0001193125-26-145524.txt | 0001193125-26-145524 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $33.03 $28.93 | ▼ −12.41% | ▼ −10.46% | $25.69 (−22.22%) |
Aug 3, 2026 8w ago | 8-K | $31.67 $30.89 | ▲ +2.46% | ▲ +1.22% | $25.69 (+18.88%) |
Aug 3, 2026 8w ago | 424B5 | $31.67 $30.89 | ▲ +2.46% | ▲ +1.22% | $25.69 (+18.88%) |
Jun 30, 2026 13w ago | 8-K | $32.72 $29.31 | ▼ −10.42% | ▼ −9.39% | $25.69 (−21.49%) |
May 7, 2026 21w ago | 8-K | $32.89 $30.01 | ▼ −8.76% | ▼ −8.78% | $25.69 (−21.89%) |
Apr 22, 2026 23w ago | DEFA14A | $34.93 $30.30 | ▼ −13.27% | ▼ −17.90% | $25.69 (−26.45%) |
Apr 7, 2026 25w ago | 8-K | $34.87 $32.96 | ▼ −5.48% | ▼ −14.02% | $25.69 (−26.33%) |
Mar 13, 2026 29w ago | Insider Cluster | $33.19 $35.05 | ▼ −5.60% | ▼ −2.02% | $25.69 (+22.60%) |
Mar 10, 2026 29w ago | Insider Cluster | $38.35 $34.87 | ▼ −9.07% | ▼ −8.92% | $25.69 (−33.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access